13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q4 2023 · Filed November 3, 2023 · Accession 0000950123-23-009395
Total Value
$188.1M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | RayzeBio, Inc. | 75525N107 | 5,158,161 | $114.5M | 60.87% |
| 2 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $32.0M | 17.00% |
| 3 | CRISPR Therapeutics AG | CRSP | 498,558 | $22.6M | 12.03% |
| 4 | Adverum Biotechnologies, Inc. | 00773U108 | 5,068,233 | $7.6M | 4.04% |
| 5 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $6.1M | 3.26% |
| 6 | Passage Bio, Inc. | PASG | 4,959,769 | $3.3M | 1.73% |
| 7 | Aligos Therapeutics, Inc. | ALGS | 2,320,381 | $1.7M | 0.92% |
| 8 | Minerva Surgical Inc. | 60343F106 | 83,684 | $275,320 | 0.15% |